Jessica Hergert | Authors

Articles

Phase 3 CheckMate-649 Study Sees Promising Survival Benefit with Frontline Nivolumab, Chemo Combo

September 22, 2020

The combination of nivolumab (Opdivo) and chemotherapy led to a statistically significant survival benefit among previously untreated patients with PD-L1–positive advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma.